Miromatrix Medical Inc. announced its participation in the H.C. Wainwright Annual Global Investment Conference on May 24th, 2022.
EDEN PRAIRIE, Minn., May 17, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced its participation in the H.C. Wainwright Annual Global Investment Conference on May 24th, 2022.
Miromatrix Medical’s management is scheduled to present at the H.C. Wainwright Annual Global Investment Conference. Interested parties can access the webcast beginning Tuesday, May 24, 2022, at 7am ET, here.
About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact:
press@miromatrix.com
